Document Classification

Section Type: RESULTS

Text: The rates of the primary end point were 0. 77 and 1. 36 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio for rosuvastatin, 0. 56 ; 95 % confidence interval [CI], 0. 46 to 0. 69 ; P < 0. 00001), with corresponding rates of 0. 17 and 0. 37 for myocardial infarction (hazard ratio, 0. 46 ; 95 % CI, 0. 30 to 0. 70 ; P = 0. 0002), 0. 18 and 0. 34 for stroke (hazard ratio, 0. 52 ; 95 % CI, 0. 34 to 0. 79 ; P = 0. 002), 0. 41 and 0. 77 for revascularization or unstable angina (hazard ratio, 0. 53 ; 95 % CI, 0. 40 to 0. 70 ; P < 0. 00001), 0. 45 and 0. 85 for the combined end point of myocardial infarction, stroke, or death from cardiovascular causes (hazard ratio, 0. 53 ; 95 % CI, 0. 40 to 0. 69 ; P < 0. 00001), and 1. 00 and 1. 25 for death from any cause (hazard ratio, 0. 80 ; 95 % CI, 0. 67 to 0. 97 ; P = 0. 02).